Welcome to our dedicated page for Medifast news (Ticker: MED), a resource for investors and traders seeking the latest updates and insights on Medifast stock.
Medifast, Inc. (NYSE: MED) generates a steady flow of news centered on its health and wellness programs, metabolic health strategy, and financial performance. As the company behind the OPTAVIA® lifestyle system and the Metabolic Synchronization™ framework, Medifast regularly issues updates that highlight how it is addressing obesity, lifestyle change, and the broader challenge of metabolic dysfunction.
Readers of this MED news page can expect coverage of quarterly and annual financial results, including trends in revenue, the number of independent active earning OPTAVIA coaches, and revenue per active earning coach. These releases often include commentary from leadership on business transformation, strategic priorities, and the company’s focus on metabolic health and long-term growth.
Medifast also publishes scientific and clinical news, such as research presented at conferences like ObesityWeek. These updates describe studies on topics including lean mass preservation on the Optimal Weight 5 & 1 Plan®, the long-term effects of anti-obesity medications, and links between sleep quality and metabolic outcomes. Such items illustrate how the company’s Scientific & Clinical Affairs team and Scientific Advisory Board contribute to evidence-based program development.
In addition, investors and observers will find corporate and strategic announcements, including the introduction of Metabolic Synchronization™, shifts in positioning from weight loss to metabolic health, and leadership or governance changes documented in press releases and related SEC filings. The company also highlights brand and educational initiatives, such as the “Health by Design” docuseries that explores cultural and environmental factors influencing metabolic health and longevity.
This news page is a central resource for following Medifast’s evolving approach to metabolic health, its OPTAVIA coach network, research milestones, and key corporate developments. For those tracking MED, it offers a consolidated view of how the company communicates its strategy, science, and financial trajectory over time.
Medifast (NYSE: MED) will report its financial results for Q1 2023, which ended on March 31, on May 1, 2023, after the market closes. This announcement will be followed by a conference call at 4:30 PM ET the same day, featuring Dan Chard, CEO, and Jim Maloney, CFO. The call will be accessible via the Investor Relations section of Medifast's website and archived until August 1, 2023. Medifast is a leader in the U.S. weight management industry, generating around $7 billion in revenue and known for its OPTAVIA brand that promotes healthy habits. The company has received recognition as one of America’s Best Mid-Sized Companies and has positively impacted over 2 million lives through its health and wellness community.
FAQ
What is the current stock price of Medifast (MED)?
What is the market cap of Medifast (MED)?
